Connect with us


Researchers develop wearable device that measures levels of disease markers via 'sweat'



San Francisco, June 20 (IANS) Researchers have developed a wearable health monitor that measures levels of important biochemicals in sweat during physical exercise, a new study said on Thursday.

According to the study published in the journal ACS Sensors, the 3D-printed monitor could someday provide a simple and non-invasive way to track health conditions and diagnose common diseases, such as diabetes, gout, kidney disease, or heart disease.

The researchers were able to accurately monitor the levels of volunteers’ glucose, lactate, uric acid, and the rate of their sweating during exercise, the study mentioned.

“I think 3D printing can make a difference to the healthcare fields, and I wanted to see if we can combine 3D printing with disease detection methods to create a device like this,” said Chuchu Chen, a Washington State University (WSU) PhD student and first author on the paper.

For their proof-of-concept health monitor, the researchers used 3D printing to make the health monitors in a unique, one-step manufacturing process.

ALSO READ:  Childbirth via C-sec soared in India between 2016 & 2021: IIT Madras

They used a single-atom catalyst and enzymatic reactions to enhance the signal and measure low levels of the biomarkers.

Sweat contains many vital metabolites that can indicate health conditions, but, unlike blood sampling, it’s non-invasive. Levels of uric acid in sweat can indicate the risk of developing gout, kidney disease, or heart disease. Glucose levels are used to monitor diabetes, and lactate levels can indicate exercise intensity, the researchers mentioned.

According to Kaiyan Qiu, Berry Assistant Professor in WSU’s School of Mechanical and Materials Engineering, the health monitor is made of very tiny channels to measure the sweat rate and biomarkers’ concentration.

As they are being fabricated via 3D printing, the micro-channels do not require any supporting structure, which can cause contamination problems as they are removed, he added.

When the researchers compared the monitors on volunteers’ arms to lab results, they found that their monitor accurately and reliably measured the concentration of the chemicals as well as the sweating rate, the study mentioned.

ALSO READ:  South Korea: Medical professors, docs to hold nationwide debate on reforms next month



Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Scientists find protein to block muscle fatigue in long Covid, Alzheimer's




New Delhi, July 14 (IANS) US researchers have identified a protein responsible for causing fatigue in people with long Covid, Alzheimer’s and other diseases.

While infections and neurodegenerative diseases like Alzheimer’s are known to cause inflammation in the brain, the patients often develop muscle problems that seem to be independent of the central nervous system.

A team led by the Washington University School of Medicine in St. Louis found that it is caused by a specific protein that travels from the brain to the muscles and leads to loss of muscle function.

The study, conducted in fruit flies and mice, also identified ways to block this process. This may help physicians treat or prevent muscle wasting caused by bacterial infections, Alzheimer’s disease, and long Covid.

Aaron Johnson, Associate professor of developmental biology explained that when people are ill, “messenger proteins from the brain travel through the bloodstream and reduce energy levels in skeletal muscle.”

ALSO READ:  Bird flu outbreak at US dairy farms cause public health concerns

The “process reduces energy levels in skeletal muscle, decreasing the capacity to move and function normally”, he said, in the study, published in the journal Science Immunology.

For the study, the team modelled three different types of diseases — an E. coli bacterial infection, a SARS-CoV-2 viral infection, and Alzheimer’s.

They found that when the brain is exposed to inflammation, it builds up damaging chemicals called reactive oxygen species. This causes brain cells to produce an immune-related molecule called interleukin-6 (IL-6), which travels throughout the body via the bloodstream.

In mice, IL-6 was responsible — and the corresponding protein in fruit flies — for reducing energy production in muscles’ mitochondria, known as the cells’ energy factories.

They also found that IL-6 activates what is called the JAK-STAT pathway in muscle, and this is what causes the reduced energy production of mitochondria.

Currently, several therapeutics already approved by the Food and Drug Administration for other diseases can block this pathway, the team said.

ALSO READ:  Childbirth via C-sec soared in India between 2016 & 2021: IIT Madras



Continue Reading


Here’s how smoking can worsen your diabetes




New Delhi, July 14 (IANS) While smoking can cause definite health issues among people of all ages, in people with diabetes, it can worsen the risk of heart disease, and stroke and make the illness harder to manage, according to a top diabetologist on Sunday.

Taking to the social media platform, Dr V Mohan, Chairman of Dr Mohan’s Diabetes Specialities Centre, explained ways in which smoking can affect people with diabetes.

He said that smoking increases insulin resistance.

“Smoking makes it harder for your body to respond to insulin, leading to higher blood sugar levels and worsening diabetes control,” the doctor said.

It also raises the risk of severe complications “such as heart disease, stroke, and peripheral artery disease.”

Smoking can also worsen blood pressure and cholesterol levels — both critical factors for managing diabetes effectively.

Smoking can also impair blood circulation in people with diabetes, and also accelerate the risk of death.

ALSO READ:  Why is early intervention key for treatment of autism?

“Smoking damages blood vessels, reducing blood flow and increasing the risk of foot ulcers and infections that can lead to amputations,” Dr Mohan said.

“People with diabetes who smoke are more likely to experience fatal health outcomes compared to non-smokers. This includes a significantly higher risk of total mortality and cardiovascular mortality,” he added.

A 2023 study by the Indian Council of Medical Research (ICMR), along with Dr Mohan and other researchers showed that India has a staggering 101 million individuals afflicted by diabetes, while the number of prediabetes stands at 136 million. The country is also home to a whopping 315 million people suffering from hypertension, and 213 million with high cholesterol, among others.

“Take charge of your health: quit smoking and manage your diabetes better,” Dr Mohan said.



Continue Reading


SGPGI doctors in Lucknow perform world's first robotic surgery




Lucknow, July 14 (IANS) Doctors at Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) here have performed the world’s first robotic surgery to treat a rare case of pelvic lipomatosis, an official said.

The official spokesperson said, “The case related to a 24-year-old man who was diagnosed with a rare disease.”

Given the complexity of the case, the surgical team at SGPGI decided to perform an augmentation cystoplasty with bilateral ureteric reimplantation. This procedure involved enlarging the bladder using a section of the patient’s intestine and repositioning the ureters to ensure proper drainage and function.

The surgery was performed for more than seven hours. Such a complex procedure where the surgical correction of both the bladder and ureter is done in one setting with a surgical robot has not been reported anywhere in the world, the official added.

Uday Pratap Singh, who led the surgery, said this operation offers numerous advantages over traditional open or laparoscopic surgery.

ALSO READ:  Study shows family history raises skin cancer risk more than sun exposure

“The use of the da Vinci Xi robotic system allowed us to perform this complex surgery with unparalleled precision. This milestone is a testament to the capabilities of robotic surgery in treating rare and challenging conditions,” he said.

The patient’s post-operative recovery has been remarkable, with significant improvement in bladder and kidney function.

“This achievement underscores SGPGI’s commitment to advancing medical science and providing cutting-edge care to patients with complex urological conditions,” said SGPGIMS Director R.K. Dhiman.



Continue Reading


Indian-American scientist discovers new biomarker for obsessive compulsive disorder




New Delhi, July 13 (IANS) A team of researchers led by an Indian-American scientist Dr Sameer Sheth has identified a specific neural activity pattern for patients who suffer from obsessive-compulsive disorder (OCD) and have undergone deep brain stimulation (DBS) for its treatment.

The team’s goal was to determine how low-frequency brain oscillations in the theta (4-8 Hertz) to alpha (8-12 Hertz) range, which have been shown in a substantial body of scientific literature to play an important role in cognitive processes, were altered in people with severe, treatment-resistant OCD.

To accomplish this, the team from Baylor College of Medicine and Texas Children’s Hospital in the US used a novel feature of contemporary DBS devices: the ability to record brain activity in addition to providing stimulation.

Unlike most studies, which are done in lab conditions, this one was done in real-life situations.

Before DBS, predictable and periodic neural activity was seen and after its activation, symptomatic reactions were seen, because DBS helps the patients let go of their phobias and embedded responses, allowing them to behave more normally, the researchers noted in the study published in the journal Nature Medicine.

ALSO READ:  Centre okays Rs 700 crore to set up institutes of pharma, medical technology

“This neuro-psychological biomarker can serve as a better litmus test to check on the improvements in the lives of people having OCD and could be used for other debilitating conditions as well for they stem from similar neural patterns,” said Dr Sheth at Baylor College of Medicine.

OCD is a prevalent and debilitating mental health illness that affects approximately 2-3 per cent of the global population. In severe circumstances, patients spend a significant amount of time engaging in repetitive compulsions and dwell on intrusive ideas.

OCD has a significant impact on the health and quality of life of patients and careers. Approximately 20-40 per cent of people with severe OCD are resistant to traditional therapies.

Since the early 2000s, DBS therapy has been utilised to control neural activity in specific areas of the brain associated with OCD symptoms.



Continue Reading


New biomarkers reveal if glaucoma patients are at high risk of losing eyesight




New Delhi, July 13 (IANS) A team of researchers has discovered blood markers that may predict whether glaucoma patients are at a higher risk of continuing to lose eyesight after normal therapy.

Glaucoma (known as kala motia in India), affects nearly 11.2 million people aged 40 and above in India. It’s the third common cause of blindness in our country, according to experts.

The main factors for glaucoma are old age and high blood pressure. Treatments to lower the intraocular pressure in the eye are available but they are not foolproof.

Researchers from University College London (UCL) and Moorfields Eye Hospital in the UK investigated whether mitochondrial function, as evaluated in white blood cells, is lower in people with glaucoma and if there is any connection at all.

The subjects were studied on the efficiency of their blood cells using oxygen, the amount of eyesight lost over time, and the levels of nicotinamide adenine dinucleotide (NAD).

ALSO READ:  Novel AI tool to instantly help assess self-harm risk

NAD is a chemical in the body that helps cells produce energy and is derived from vitamin B3 in the food.

Firstly, the researchers observed that particular cells in the blood, known as peripheral blood mononuclear cells, use oxygen differently in persons with glaucoma.

Secondly, people with glaucoma have lower amounts of NAD in their blood cells, which means lower oxygen consumption in their body cells, according to the study published in the journal Nature Medicine.

“White blood cell mitochondrial function and NAD levels, if introduced as a clinical test, would enable clinicians to predict which patients are at higher risk of continued vision loss, allowing them to be prioritised for more intensive monitoring and treatment,” said Senior author Professor David (Ted) Garway-Heath from UCL’s Institute of Ophthalmology and Moorfields Eye Hospital.

If research proves that low mitochondrial function or NAD is a factor, then new treatments can be introduced, said authors.

The researchers are now running a major clinical research to see if high-dose vitamin B3 can improve mitochondrial function and minimize vision loss, opening up new avenues.

ALSO READ:  ‘One in every five individuals is affected by fatty liver’



Continue Reading